ADVERTISEMENT

Alkyl Amines Q4 Results Review - Long-Term Volume Guidance Remains Intact: Motilal Oswal

Ebitda in line; Ebitdam expands.

<div class="paragraphs"><p>Alkyl Amines Chemicals Ltd.'s plants. (Source: Company website)</p></div>
Alkyl Amines Chemicals Ltd.'s plants. (Source: Company website)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 

Motilal Oswal Report

Alkyl Amines Chemicals Ltd. reported in-line revenue in Q4 FY23. Gross margin contracted to 46.4%. Ebitda was also in line at Rs 769 million with Ebitdam at 18.7% (up 80 basis point QoQ).

Operating expenses were higher due to elevated coal prices even as the company was able to maintain its market share in FY23.

The pharma industry outlook appears positive after a couple of years of drag post-Covid due to de-stocking on account of inventory buildup during the pandemic. That being said, the management focus and long-term guidance of 10-15% volume growth remained intact.

The average utilisation of both the acetonitrile plants was 60-65% in FY23 with current realisations being Rs 150/kg. In USD terms, it is one of the lowest values right now due to a glut in the market but the management expects the prices of acetonitrile to rebound in FY24.

Capacity expansion of Ethyl Amines in Kurkumbh (100 tonnes per day capacity) is on track and is expected to be commissioned by July 2023. Capex envisaged for the same is Rs 4 billion.

Alkyl Amines had also commissioned Di-Ethyl Ketone in February 2023, the plant of which has now stabilised with other four products set to be commissioned in the next 24 months.

Click on the attachment to read the full report:

Motilal Oswal Alkyl Amines Q4FY23 Results Review.pdf
Opinion
Sanofi India Q1 Results Review — Strong Earnings; Focus On Rx: Centrum Broking

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.